이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

DCIS: RECAST 시험관 상피내 암종: 치료로서의 능동 감시 적합성을 위한 조건 재평가

2026년 11월 12일 업데이트: QuantumLeap Healthcare Collaborative

DCIS: RECAST 시험 - 상피내관 암종: 치료로서의 능동 감시 적합성을 위한 조건 재평가: 유방암 예방 예비 연구

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.

Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

연구 개요

상세 설명

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.

Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:

  • Provide blood sample to understand their immune status
  • Provide saliva sample for genetic testing
  • Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Participants will be followed annually for 10 years.

연구 유형

중재적

등록 (추정된)

400

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Tammy Neseth, MA, CCRP
  • 전화번호: +1 (507) 269-8060
  • 이메일: t.neseth@qlhc.org

연구 연락처 백업

  • 이름: Sabrina Mayhew, Ph.D. Nursing
  • 전화번호: +1 (888) 282-7099
  • 이메일: s.mayhew@qlhc.org

연구 장소

    • California
      • Berkeley, California, 미국, 94158
        • 모병
        • Berkeley Outpatient Center
        • 연락하다:
        • 수석 연구원:
          • Jordan Jackson, MD
        • 연락하다:
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope -Duarte Cancer Center
        • 수석 연구원:
          • Jennifer Tseng, MD
        • 연락하다:
          • Mellissa Henry, RN, MSN, FNP-C
          • 전화번호: 626-713-8895
          • 이메일: mehenry@coh.org
      • Irvine, California, 미국, 92618
        • 모병
        • City of Hope - Lennar Foundation Cancer Center
        • 수석 연구원:
          • Jennifer Tseng, MD
        • 연락하다:
          • Mellissa Henry, RN, MSN, FNP-C
          • 전화번호: 626-713-8895
          • 이메일: mehenry@coh.org
      • Los Angeles, California, 미국, 90095
        • 모병
        • UCLA
        • 연락하다:
        • 수석 연구원:
          • Mediget Teshome, MD
      • San Francisco, California, 미국, 94158
        • 모병
        • UCSF
        • 수석 연구원:
          • Jordan Jackson, MD
        • 연락하다:
      • South Pasadena, California, 미국, 91030
        • 모병
        • City of Hope
        • 수석 연구원:
          • Jennifer Tseng, MD
        • 연락하다:
          • Mellissa Henry, RN, MSN, FNP-C
          • 전화번호: 626-713-8895
          • 이메일: mehenry@coh.org
      • Walnut Creek, California, 미국, 94598
        • 모병
        • John Muir Health
        • 연락하다:
        • 수석 연구원:
          • Monica Eigelberger, MD
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • 모병
        • MedStar Washington Hospital Center
        • 수석 연구원:
          • Marc Boisvert, MD
        • 연락하다:
    • Florida
      • Tampa, Florida, 미국, 33612
        • 모병
        • Moffitt Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Laura Kruper, MD
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Winship Cancer Institute, Emory University
        • 수석 연구원:
          • Clara Farley, MD
        • 연락하다:
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60637
    • Minnesota
      • Maple Grove, Minnesota, 미국, 55369
        • 모병
        • Maple Grove Cancer Center
        • 연락하다:
          • Oncology Access Nurse
          • 전화번호: 612-624-2620
          • 이메일: ccinfo@umn.edu
        • 수석 연구원:
          • Jane Hui, MD
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota
        • 연락하다:
          • Oncology Access Nurse
          • 전화번호: 612-624-2620
          • 이메일: ccinfo@umn.edu
        • 수석 연구원:
          • Jane Hui, MD
      • Minneapolis, Minnesota, 미국, 55404
      • Saint Louis Park, Minnesota, 미국, 55426
      • Saint Paul, Minnesota, 미국, 55101
    • New Jersey
      • Englewood, New Jersey, 미국, 07631
        • 모병
        • Englewood Hospital and Medical Center
        • 연락하다:
        • 수석 연구원:
          • Jennifer Marti, MD
    • New York
      • New York, New York, 미국, 10011
        • 모병
        • Mount Sinai Chelsea
        • 수석 연구원:
          • Tara Balija, MD
        • 연락하다:
          • Contact: Site Public Contact
          • 전화번호: 212-824-7309
          • 이메일: CRSU@mssm.edu
      • New York, New York, 미국, 10029
        • 모병
        • Icahn School of Medicine at Mount Sinai
        • 수석 연구원:
          • Tara Balija, MD
        • 연락하다:
          • Contact: Site Public Contact
          • 전화번호: 212-824-7309
          • 이메일: CRSU@mssm.edu
      • New York, New York, 미국, 10019
        • 모병
        • Mount Sinai West
        • 수석 연구원:
          • Tara Balija, MD
        • 연락하다:
          • Contact: Site Public Contact
          • 전화번호: 212-824-7309
          • 이메일: CRSU@mssm.edu
      • New York, New York, 미국, 10003
        • 모병
        • Mount Sinai Union Square
        • 수석 연구원:
          • Tara Balija, MD
        • 연락하다:
          • Contact: Site Public Contact
          • 전화번호: 212-824-7309
          • 이메일: CRSU@mssm.edu
      • The Bronx, New York, 미국, 10461
        • 모병
        • Montefiore Medical Center (Hutchinson Campus Tower 1)
        • 연락하다:
        • 수석 연구원:
          • Sheldon Feldman, MD
        • 연락하다:
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Ton Wang, MD
      • Winston-Salem, North Carolina, 미국, 27157
    • Pennsylvania
      • Bryn Mawr, Pennsylvania, 미국, 19010
        • 모집하지 않고 적극적으로
        • Bryn Mawr Hospital
      • Paoli, Pennsylvania, 미국, 19301
        • 모집하지 않고 적극적으로
        • Paoli Hospital
      • Wynnewood, Pennsylvania, 미국, 19096
        • 모집하지 않고 적극적으로
        • Lankenau Medical Center
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University Medical Center
        • 수석 연구원:
          • Ingrid Meszoely, MD
        • 연락하다:
          • Oncology nursing
          • 전화번호: 1-800-811-8480
          • 이메일: cip@vumc.org
        • 연락하다:
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • 모병
        • Huntsman Cancer Institute
        • 수석 연구원:
          • Kirstyn Brownson, MD
        • 연락하다:
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • 모병
        • Virginia Commonwealth University
        • 연락하다:
        • 수석 연구원:
          • Kandace McGuire, MD
    • Washington
      • Seattle, Washington, 미국, 98109
        • 모병
        • Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
        • 수석 연구원:
          • Sara Javid, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

A. Female, at least 18 years old

B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion

  • Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.

C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial

D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.

E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.

F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant

G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment

H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent

I. Willingness and ability to provide tumor samples for research

Exclusion Criteria:

A. Pregnant or actively breastfeeding women

B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history

C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer

D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND

E. Ongoing treatment for DCIS other than what is specified in this protocol

F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements

G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures

*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)

H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment

I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.

J. Severe allergy or reaction history to MRI contrast.

K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: chemoprevention therapy per investigator choice

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally.

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years.

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally

For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.

For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.

실험적: Testosterone + Anastrazole (T+Ai)

White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.

다른 이름들:
  • T+아이
실험적: Elacestrant

Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.

실험적: Endoxifen

(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Patients remaining on active surveillance at 7 months
기간: 7 months

Fraction of patients remaining on active surveillance at 7 months compared to control

7 months

2차 결과 측정

결과 측정
측정값 설명
기간
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
기간: 6 months

Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

6 months
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
기간: 3 months

Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

3 months
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
기간: 3 years

Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years

3 years
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
기간: 6 months

Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment)

6 months
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
기간: 6 months

Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume

6 months
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
기간: 6 months

% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density

6 months
Determine adherence to active surveillance protocol
기간: 5 years

Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index.

5 years
Change in artificial intelligence predicted risk based on mammography
기간: 5 years

Correlation of BPE change with agent and compare to quantitative imaging density

5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
기간: 7 months

evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance

7 months
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
기간: 7 months

Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS)

7 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
  • 수석 연구원: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 17일

기본 완료 (추정된)

2028년 11월 1일

연구 완료 (추정된)

2033년 11월 1일

연구 등록 날짜

최초 제출

2023년 9월 22일

QC 기준을 충족하는 최초 제출

2023년 10월 4일

처음 게시됨 (실제)

2023년 10월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다